Michael Burchmore
Impact in
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 8
- HER2/EGFR in Cancer Research 7
- Cancer Treatment and Pharmacology 6
- Peptidase Inhibition and Analysis 4
-
- Monoclonal and Polyclonal Antibodies Research 2
- Co-authors
- Dennis J. Slamon (5 shared papers)Maureen Murphy (3 shared papers)Melody Cobleigh (4 shared papers)Charles L. Vogel (4 shared papers)Louis Fehrenbacher (4 shared papers)Lyndsay N. Harris (4 shared papers)William Novotny (4 shared papers)Debu Tripathy (4 shared papers)
- Journals
- European Journal of Cancer (3 papers)Journal of Clinical Oncology (3 papers)Oncology (1 paper)Orthopedics (1 paper)PubMed (1 paper)
- Partner nations
- United StatesCanada
In The Last Decade
Michael Burchmore
9 papers receiving 2.0k citations
Michael Burchmore's Hit Papers
Peers
Comparison fields: 5 of 84
- Oncology 1.6k
- Radiology, Nuclear Medicine and Imaging 906
- Cancer Research 352
- Immunology and Allergy 79
- Genetics 116
Countries citing papers authored by Michael Burchmore
This map shows the geographic impact of Michael Burchmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Burchmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Burchmore more than expected).
Fields of papers citing papers by Michael Burchmore
This network shows the impact of papers produced by Michael Burchmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Burchmore. The network helps show where Michael Burchmore may publish in the future.
Co-authors
The 20 scholars most cited alongside Michael Burchmore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Hit paper breakdown → | 2002 | 1508 |
| 2 | 2001 | 145 | |
| 3 | 2001 | 145 | |
| 4 | 2002 | 111 | |
| 5 | Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). | 1999 | 39 |
| 6 | 1994 | 35 | |
| 7 | 2023 | 16 | |
| 8 | 2001 | 11 | |
| 9 | 1999 | 8 |
About Michael Burchmore
Michael Burchmore is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Pharmacology and Pulmonary and Respiratory Medicine, having authored 9 papers that have together received 2.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (6 papers), Peptidase Inhibition and Analysis (4 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Advanced Breast Cancer Therapies (1 paper), Analytical Methods in Pharmaceuticals (1 paper), Inflammatory mediators and NSAID effects (1 paper) and Breast Cancer Treatment Studies (1 paper). The work is most often cited by research in Oncology (1.6k citations), Radiology, Nuclear Medicine and Imaging (906 citations), Cancer Research (352 citations), Immunology and Allergy (79 citations) and Genetics (116 citations). Michael Burchmore has collaborated with scholars based in United States and Canada. Frequent co-authors include Dennis J. Slamon, Maureen Murphy, Melody Cobleigh, Charles L. Vogel, Louis Fehrenbacher, Lyndsay N. Harris, William Novotny, Debu Tripathy, Steven Shak and Stanford J. Stewart. Their work appears in journals such as European Journal of Cancer, Journal of Clinical Oncology, Oncology, Orthopedics and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.